Aspen Acquires AstraZeneca Anesthetics Portfolio Ex-US

Continuing its divesture of non-core assets, AstraZeneca PLC has licensed rights to its global anesthetics portfolio outside the US to South Africa's Aspen Global Incorporated

Magnifying glass

The UK's second-biggest drug maker is licensing seven established anesthetic medicines to Aspen Global Incorporate (AGI),those beingDiprivan for general anesthesia, topical anesthetic EMLA and five local anesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest; see table below for full details).

Under the deal, announced June 9, AGI acquires commercialization rights outside the US to AstraZeneca’s portfolio of anesthetic medicines for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip